CO5170404A1 - Terapia para melanomas - Google Patents

Terapia para melanomas

Info

Publication number
CO5170404A1
CO5170404A1 CO00025236A CO00025236A CO5170404A1 CO 5170404 A1 CO5170404 A1 CO 5170404A1 CO 00025236 A CO00025236 A CO 00025236A CO 00025236 A CO00025236 A CO 00025236A CO 5170404 A1 CO5170404 A1 CO 5170404A1
Authority
CO
Colombia
Prior art keywords
patient
pegylated interferon
interferon alfa
time
melanomas
Prior art date
Application number
CO00025236A
Other languages
English (en)
Inventor
Rybak Mary Eleln
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5170404A1 publication Critical patent/CO5170404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

El uso de interferon alfa pegilado para la manufactura de un medicamento para el tratamiento de un paciente que tiene melanoma que ha sido removido quirúrgicamente, en donde dicho medicamento es administrado a dicho paciente en una dosis terapéuticamente eficaz de interferon alfa pegilado por un periodo de tiempo suficiente para incrementar el tiempo de supervivencia libre de progresión.El uso de interferon alfa pegilado para la manufactura de un medicamento para el tratamiento de un paciente que tiene melanoma cutáneo que ha sido removido quirúrgicamente, en donde dicho medicamento es administrado a dicho paciente en una dosis terapéuticamente eficaz de interferon alfa pegilado una vez por semana por un periodo de tiempo suficiente para incrementar el tiempo de supervivencia libre de progresión.
CO00025236A 1999-04-08 2000-04-06 Terapia para melanomas CO5170404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
CO5170404A1 true CO5170404A1 (es) 2002-06-27

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00025236A CO5170404A1 (es) 1999-04-08 2000-04-06 Terapia para melanomas

Country Status (22)

Country Link
EP (3) EP1043026B1 (es)
JP (1) JP2000319195A (es)
CN (1) CN1390132A (es)
AR (1) AR023398A1 (es)
AT (3) ATE496631T1 (es)
AU (1) AU771569B2 (es)
BR (1) BR0009646A (es)
CA (1) CA2303992A1 (es)
CO (1) CO5170404A1 (es)
CY (1) CY1108922T1 (es)
DE (3) DE60041290D1 (es)
DK (2) DK1043026T3 (es)
ES (2) ES2319776T3 (es)
HK (2) HK1032349A1 (es)
HU (1) HU230057B1 (es)
MY (1) MY126763A (es)
NO (1) NO328111B1 (es)
PE (1) PE20010027A1 (es)
PT (2) PT1535622E (es)
TW (1) TWI292320B (es)
WO (1) WO2000061175A2 (es)
ZA (1) ZA200108173B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360254B (es) 2011-03-10 2018-10-26 Pfizer Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
AR023398A1 (es) 2002-09-04
BR0009646A (pt) 2002-02-05
CA2303992A1 (en) 2000-10-08
EP1043026A2 (en) 2000-10-11
EP2025344A1 (en) 2009-02-18
EP2025344B1 (en) 2011-01-26
EP1535622A1 (en) 2005-06-01
CN1390132A (zh) 2003-01-08
AU771569B2 (en) 2004-03-25
AU4204600A (en) 2000-11-14
DK1043026T3 (da) 2005-07-04
DK1535622T3 (da) 2009-04-20
DE60020444T2 (de) 2006-05-04
PE20010027A1 (es) 2001-02-05
DE60045591D1 (de) 2011-03-10
JP2000319195A (ja) 2000-11-21
ES2239954T3 (es) 2005-10-16
NO20014852D0 (no) 2001-10-05
HU230057B1 (hu) 2015-06-29
ATE496631T1 (de) 2011-02-15
DE60041290D1 (de) 2009-02-12
PT1535622E (pt) 2009-03-19
ES2319776T3 (es) 2009-05-12
ATE296639T1 (de) 2005-06-15
HK1075416A1 (en) 2005-12-16
HUP0200775A3 (en) 2002-09-30
EP1535622B1 (en) 2008-12-31
EP1043026A3 (en) 2000-12-20
MY126763A (en) 2006-10-31
ATE419001T1 (de) 2009-01-15
DE60020444D1 (de) 2005-07-07
WO2000061175A2 (en) 2000-10-19
ZA200108173B (en) 2003-01-06
TWI292320B (en) 2008-01-11
EP1043026B1 (en) 2005-06-01
CY1108922T1 (el) 2014-07-02
HUP0200775A2 (en) 2002-08-28
PT1043026E (pt) 2005-09-30
WO2000061175A3 (en) 2001-02-01
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
HK1032349A1 (en) 2001-07-20

Similar Documents

Publication Publication Date Title
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
PT95169A (pt) Forma de dosagem para administracao de glipizida hipoglicemica por via oral
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
MX9203443A (es) Una forma de dosis para el suministro retardado de un farmaco.
NO20032027L (no) Effektive antitumorbehandlinger
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
CO5170404A1 (es) Terapia para melanomas
AR029160A1 (es) El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
AR016308A1 (es) Uso de inhibidores de la fosfodiesterasa 4 o sus sales, medicamento para el tratamiento de la rinitis alergica que contiene los compuestos mencionados yprocedimiento para preparar dicho medicamento.
DK1265629T3 (da) Anvendelse af væksthormon i lav dosis
MX9306998A (es) Una composicion terapeutica de tandospirona y forma de dosis paraadministrarla.
ES2166778T3 (es) Factor de crecimiento ii de tipo insulina como agente antitumoral.
PE20010226A1 (es) Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica

Legal Events

Date Code Title Description
FC Application refused